Company intelligence / Profile preview

mbiomics

Munich, Bavaria, Germanymbiomics.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

mbiomics has achieved technological proof-of-concept for its proprietary analytics platform, enabling the rational selection and design of complex live bacterial therapeutics. The company is building a pipeline targeting severe and chronic diseases by restoring healthy gut microbiota. No clinical results have been published yet; the focus remains on preclinical development and candidate identification.

Therapeutic areas: GastroenterologyImmunologyOncology
Modalities: Live biotherapeutic product therapyMicrobial therapyBiologic (as umbrella for live microbial consortia)
Industry: Biotech

Drug pipeline

1 asset

MBX-116

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025. Strategic partnerships anticipated as part of growth strategy post-Series A funding.

Beyond the preview

Go deeper on mbiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mbiomics.

Explore the full profile